Filing Details
- Accession Number:
- 0001562180-21-006652
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-27 16:11:34
- Reporting Period:
- 2021-10-25
- Accepted Time:
- 2021-10-27 16:11:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1395937 | Syndax Pharmaceuticals Inc | SNDX | Pharmaceutical Preparations (2834) | 320162505 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1507220 | A Michael Metzger | C/O Syndax Pharmaceuticals, Inc. 35 Gatehouse Drive, Building D, Floor 3 Waltham MA 02451 | President And Coo | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-10-25 | 44,704 | $7.20 | 62,363 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-10-25 | 44,704 | $19.13 | 17,659 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-10-26 | 16,296 | $7.20 | 33,955 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-10-26 | 16,296 | $19.20 | 17,659 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (Right to buy) | Disposition | 2021-10-25 | 44,704 | $0.00 | 44,704 | $7.20 |
Common Stock | Stock Options (Right to buy) | Disposition | 2021-10-26 | 16,296 | $0.00 | 16,296 | $7.20 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2025-06-01 | No | 4 | M | Direct | |
0 | 2025-06-01 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
- The share price ranged from $19.00 to $19.48
- The sales price ranged from $19.01 to $19.33
- This option is fully vested.